Heterogeneity of driver genes and therapeutic implications in colorectal cancer

Annals of Oncology

Volumn 26, Issue 8, 2015, Pages 1523-1525

  Dienstmann, R ^a,b   Cervantes, A ^c  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b SAGE BIONETWORKS   (United States)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

CANCER GROWTH; CANCER PATIENT; CANCER SCREENING; CLONAL VARIATION; COLORECTAL CANCER; EDITORIAL; EXON; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENE STRUCTURE; GENETIC HETEROGENEITY; HETEROZYGOSITY; HUMAN; NEXT GENERATION SEQUENCING; ONCOGENE K RAS; ONCOGENE N RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR CELL; CARCINOMA; COLORECTAL TUMOR; GENETICS;

CARCINOMA; COLORECTAL NEOPLASMS; HUMANS;

EID: 84941654132     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv229     Document Type: Editorial

References (16)

1. Normanno N, Rachiglio AM, Lambiase M et al. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Ann Oncol 2015; 26: 1710-1714.
2. Paguirigan AL, Smith J, Meshinchi S et al. Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia. Sci Transl Med 2015; 7: 281re2.
3. McGranahan N, Favero F, de Bruin EC et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med 2015; 7: 283ra54.
4. Brannon AR, Vakiani E, Sylvester BE et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol 2014; 15: 454.
5. Ahronian LG, Sennott EM, Van Allen EM et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov 2015; 5: 358-367.
6. Kristensen T, Clemmensen O, Hoejberg L. Low incidence of minor BRAF V600 mutation-positive subclones in primary and metastatic melanoma determined by sensitive and quantitative real-time PCR. J Mol Diagn 2013; 15: 355-361.
7. de Biase D, Cesari V, Visani M et al. High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas. J Clin Endocrinol Metab 2014; 99: E1530-E1538.
8. Sottoriva A, Kang H, Ma Z et al. A Big Bang model of human colorectal tumor growth. Nat Genet 2015; 47: 209-216.
9. Molinari F, Felicioni L, Buscarino M et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 2011; 17: 4901-4914.
10. Tougeron D, Lecomte T, Pagès JC et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol 2013; 24: 1267-1273.
11. Laurent-Puig P, Pekin D, Normand C et al. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res 2015; 21: 1087-1097.
12. Van Cutsem E, Lenz HJ, Köhne CH et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015; 33: 692-700.
13. Sorich MJ, Wiese MD, Rowland A et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a metaanalysis of randomized, controlled trials. Ann Oncol 2015; 26: 13-21.
14. Zhou Q, Zhang XC, Chen ZH et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 3316-3321.
15. Ono A, Kenmotsu H, Watanabe M et al. Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation. Ann Oncol 2014; 25: 1948-1953.
16. Atreya CE, Corcoran RB, Kopetz S. Expanded RAS: refining the patient population. J Clin Oncol 2015; 33: 682-685.